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Abstract: Malignant tumors behave dynamically as cell communities governed by ecological
principles. Massive sequencing tools are unveiling the true dimension of the heterogeneity of these
communities along their evolution in most human neoplasms, clear cell renal cell carcinomas (CCRCC)
included. Although initially thought to be purely stochastic processes, very recent genomic analyses
have shown that temporal tumor evolution in CCRCC may follow some deterministic pathways
that give rise to different clones and sub-clones randomly spatially distributed across the tumor.
This fact makes each case unique, unrepeatable and unpredictable. Precise and complete molecular
information is crucial for patients with cancer since it may help in establishing a personalized therapy.
Intratumor heterogeneity (ITH) detection relies on the correctness of tumor sampling and this is
part of the pathologist’s daily work. International protocols for tumor sampling are insufficient
today. They were conceived decades ago, when ITH was not an issue, and have remained unchanged
until now. Noteworthy, an alternative and more efficient sampling method for detecting ITH has
been developed recently. This new method, called multisite tumor sampling (MSTS), is specifically
addressed to large tumors that are impossible to be totally sampled, and represent an opportunity to
improve ITH detection without extra costs.
Keywords: clear cell renal cell carcinoma; tumor evolution; tumor ecology; intratumor heterogeneity;
multisite tumor sampling; targeted therapy
1. Introduction
Clear cell renal cell carcinoma (CCRCC) is nowadays a health problem of major concern in
developed societies. The tumor is an aggressive histologic subtype of renal cancer whose incidence
is expected to be increased in the future due to the increasing rate of obesity and the ageing
population occurring in Western countries [1]. CCRCC shows a well-known resistance to radio-
and chemotherapy [2]. However, anti-angiogenic drugs and immune checkpoint blockade are showing
promising therapeutic results. At present, three therapeutic options have demonstrated an overall
survival improvement: cabozantinib and nivolumab in second or subsequent lines [3], and the
combination of nivolumab and ipilimumab in first line therapy [4].
Pathologists are the medical specialists who handle surgical specimens and decide which parts
of the tumor must be included for microscopic, immunohistochemical (IHC) and molecular analyses.
Tumor representativeness is becoming a critical issue in modern pathology, either when selecting
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fragments from large resected tumors or when obtaining tissue cores from tumors prior to surgical
resection for diagnostic and/or therapeutic purposes. Increasing evidences are showing in the last
times that current sampling strategies may not be giving a complete information about the histological
and/or molecular alterations that are present in many tumors of different topographies [5–9]. These
inconsistencies rise serious concerns among oncologists [10]. Pathologists, however, seem not to be
aware of this central problem since sampling protocols still remain unmodified in routine work.
Intratumor heterogeneity (ITH) is at the basis of the lack of tumor representativeness in many
tumor samplings. Although well known for decades, the ITH molecular information is having a
significant clinical impact in the last years. The arrival of targeted therapies has increased the need of
very precise information about ITH since it is observed in many tumor types and represents a major
hurdle for effective therapy, provoking therapeutic resistance and metastatic recurrence [11]. In this
sense, Gerlinger et al. [12] unveiled in 2012 to what extent this phenomenon is present in clear cell
renal cell carcinomas, describing the molecular heterogeneity of these tumors across different regions
within the same tumor.
A new tumor sampling strategy has been developed very recently to improve ITH detection
in routine practice [13]. This new method, termed multi-site tumor sampling (MSTS), has been
successfully applied to CCRCC, although it can be applied to any tumor large enough as to make
impossible a total sampling. Interestingly, MSTS outperforms routine sampling protocols in detecting
ITH while keeping the cost fixed [14].
The present paper focuses on the importance of tumor representativeness in modern Oncology.
A correct tumor sampling is mandatory for this purpose. CCRCC is a good example since it is a
well-known paradigm of ITH. More specifically, this paper revisits some basic concepts and applied
clinical issues of CCRCC evolution. Tumor ecology and spatial and temporal evolution constrains are
then reviewed to contextualize the urgent need of an appropriate tumor analysis. Also, this overview
details a more advantageous alternative for tumor sampling supported by a in silico modeling with
clinical validation.
2. Tumors as Dynamic Cell Communities Guided by Ecological Principles
Neoplasia encompasses a number of complex and largely unknown processes with a metabolic
background [15]. Although pathologists risk thinking of tumors under the microscope as static
combinations of cells arranged in different backgrounds organized in varied architectural structures,
malignant tumors are complex communities of cells evolving in time with individuals permanently
interacting each other. The idea of comparing malignant tumors with other biological communities
behaving in a swarm-like manner [16] following similar ecological rules [17,18] is not new. The adaptive
mechanisms of tumor cells to their ever-changing habitat are a crucial issue to survive, grow and
progress. Epithelial-mesenchymal transition (EMT), and its reversal process (mesenchymal-epithelial
transition), are good examples of this dynamic adaptative capacity that can be eventually targeted [19].
A paradoxical effect of EMT is, for example, the development of low-grade metastases in high-grade
CCRCC [20]. This tumor behavior, as defined in Ecology, can be synthesized in four models:
predation, mutualism, commensalism and parasitism [21]. ITH is known to be induced genetically
and epigenetically by interaction with the local tumor microenvironment. Interestingly, tumor
microenvironment changes from tumor to tumor, from organ to organ, and even from region to
region within the same tumor.
Swarming is defined as the collective behavior of a community of individuals without any
centralized guidance or government. This behavior is based essentially on the sum of myriads of
neighbor-to-neighbor communications, and is very common in Nature. Tumor cells reproduce this
behavior when a specific subgroup within a community of malignant cells of a tumor decides to
invade neighbor tissues or metastasize to other organs far away [16]. The collective acquisition of
specific properties of tumor cells composing specific tumor compartments is a well-documented event
in most tumors, CCRCC included [22]. This phenomenon applies also for tumor microenvironment.
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For example, a selective loss of PD-L1 expression has been detected in tumor infiltrating lymphocytes
(TIL) taking part of the vein/caval tumor thrombi compartment of CCRCC [23].
Predation refers to an inter-individual relationship in which one individual benefits the other
killing it. The attack of some T-cells co-localized with tumor cells that is so evident under the
microscope in some CCRCC is a good example of predation. This phenomenon has been investigated
mainly in breast tumors. For example, a high co-localization of immune and tumor cells was associated
to higher 10-year survival in Her2+ breast carcinomas [24]. In the same sense, the pattern of the
PD-1/PD-L1 axis expression in tumor cells and in TIL predicts tumor aggressiveness and survival also
in Her2+ breast cancer [25]. Although PD-1/PD-L1 axis blockade is being used with great promise
for advanced CCRCC treatment, none study of co-localization of immune and cancer cells in these
neoplasms has been published so far.
Cancer cells not always compete for scarce resources. Mutualism applied to cancer refers to
the cooperation of two different cell clones for the same benefit thus favoring tumor growth and
invasion. This process usually implicates extracellular matrix proteins, such as metalloproteinases and
fibronectin, as happens in a zebrafish-melanoma xenograft model [26]. Interestingly, this cooperation
has also been identified between tumor cells and stromal inflammatory cells [27].
Examples of commensalism have also been reported in neoplasia. Commensalism describes the
relationship of two different cell clones for the benefit of one of them, although the other being not
damaged. Also, this process refers to tumor cells and microenvironment cells interactions, for example,
the cooperation between tumor cells and tumor-associated fibroblasts favoring tumor progression and
metastases [28,29]. High levels of fibroblast activation protein (FAP) have been correlated with tumor
size, high grade, high stage and shorter survival in CCRCC, both in primary tumors [30] and in its
paired metastases [31]. In this regard, the IHC detection of FAP in the stromal tumor fibroblasts could
be a potential biomarker of early lymph node metastatic status and therefore could account for the
poor prognosis of FAP positive CCRCC [29]. Even more, recent evidences have shown that tumor
microenvironment may vary in an organ-related way along the multiple disseminated metastases of
the same tumor [32].
In these collective relationships, some situations lead to an individual to benefit from another
damaging it, although not enough so as to destroy it (as happens in predation). In Ecology, this situation
is termed parasitism and also occurs in tumor cell communities, for example, when considering
the systemic damage generated by the local invasiveness and the metastatic spread of a tumor.
This situation could be conceived as a reversal manifestation of the Warburg effect [33], and may
explain the frequent association of tumor desmoplasia and biological aggressiveness that occur in
many neoplasms.
3. Spatial and Temporal Evolution in Clear Cell Renal Cell Carcinomas
As mentioned in previous paragraphs, several researchers have shown how cancer can be
regarded from an ecological perspective that governs tumor evolution [17,34,35]. Obvious ethical
reasons do not allow the analysis of the temporal evolution of any tumor. However, bioinformatic
tools can infer this process by reconstructing the past chronology. Data coming from the molecular
analysis of the tumor tissue obtained from the patient can be phylogenetically analyzed. For example,
a mathematical modeling has recently defined the timing in the evolution of CCRCC showing that
the tumor originates as soon as in the childhood or adolescence of the patient, and remains silent for
decades until appearing symptomatic [36]. More exactly, these early events in CCRCC consist in 3p
loss with concurrent 5q gain as a result of chromothrypsis, a process that occurs only in a few hundreds
of cells [36].
Four models of tumor evolution have been proposed: linear, branched, punctuated and
neutral [37]. With respect to the evolutionary patterns, CCRCC may follow branched or punctuated
models, as reported very recently [38].
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In the linear evolution model, the new sequential driver mutations that appear across the time
vanishes the previous ones due to a strong selective advantage. Such tumor evolution was proposed
long time ago for some examples of colorectal adenocarcinomas [39]. Linear evolution is an example
of Darwinian model.
Branched evolution model has been identified in many human tumors, CCRCC included [12],
and basically consists in a truncal mutation shared by all tumor regions followed by clonal, sub-clonal
and private mutations across the different tumor regions. The resulting evolutionary trees are
shaped by the different accumulative clonal and sub-clonal divergences. Sub-clonal driver mutations
and convergent evolution are two features observed in the branched evolution of CCRCC [12,40].
Interestingly, the coexistence of multiple sub-clones in branched tumors opens the door for the
possibility of some type of sub-clonal cooperation following any of the ecological patterns described
before. Branched evolution also follows a Darwinian model.
Also called the “Big Bang” model [41], the punctuated evolution model is characterized by a large
number of genomic changes occurring at very early stages of tumor evolution. ITH is very high at the
beginning but decreases progressively across the time as a result of the high selective predominance
of very few clones. Typically, tumors developed in a punctuated model display low ITH and high
amounts of single chromosomal rearrangements, a phenomenon termed chromothrypsis present in
several human tumors, including a subset of CCRCC [36]. Punctuated evolution is also a Darwinian
model of tumor evolution.
Neutral evolution is a paradigm of a non-Darwinian model with extremely high ITH in which
natural selection driven by sub-clonal mutations and convergent evolution does no take place.
Most CCRCC follow either branched or punctuated evolution models. In this regard, a recent
multicenter study analyzing 1206 regions from 101 patients has demonstrated that CCRCC display
up to seven distinct evolutionary subtypes [38]. Three of these subtypes (multiple clonal drivers,
BAP1 driven and VHL wild type tumors) followed a punctuated model, were associated to aggressive
clinical behavior and showed early 9p and 14q losses, high chromosomal complexity and low ITH.
By contrast, three other subtypes (PBRM1→ SETD2, PBRM1→ PI3K and PBRM1→ SCNA driven
tumors) followed a branched model and were associated to a less aggressive behavior, with late 9p
and 14q losses, low chromosomal complexity and high ITH. The sub-clonal acquisition of BAP1 or
other mutations linked to clinical aggressiveness marked the inflexion from indolence towards rapid
evolution in this group of CCRCC. Finally, a seventh subtype (VHL mono-driver) was characterized
by low chromosomal complexity and low ITH. Typically, this last subtype did not display 9p or 14q
losses. These molecular subtypes were associated with classic gross (tumor diameter) and histological
(Furhman’s grade, TNM staging, presence of necrosis) parameters and have prognostic implications
for patients [38].
With respect to the development of metastases, CCRCC have shown specific routes in a thorough
analysis of 575 primary and 335 metastatic biopsies in 100 patients with metastatic CCRCC [42].
This multicenter study included three different cohorts of paired primary and metastatic samples of
CCRCC with clinical follow up. The analysis also included samples obtained from the tumor thrombi
in 24 cases. In summary, the aggressive evolutionary subtypes, that is, tumors with high chromosomal
complexity and low ITH displayed a rapid progression to multiple metastases, whereas the opposite,
that is, tumors with low chromosomal complexity but high ITH showed an attenuated temporal
tumor progression, with tendency to develop late single metastasis. Finally, tumors within the seventh
subtype never metastasized.
Although ITH is a main contributor to the development of therapeutic resistance, the mechanisms
that underlie this causal inter-relation provide an example of natural selection through evolutionary
adaptation [43]. Genetic and epigenetic changes contribute to modify and adapt tumor cell fitness to
the new requirements, thus selecting specific clones not only to invade or metastasize, but also to resist
to drugs. Targeted therapies, by definition, select tumor cell populations for resistance, this process
being Darwinian in essence [44]. However, therapeutic resistance does not solely concern tumor cells;
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the local tumor microenvironment also takes part in this process, for example, when the hypoxic status
observed in some regions of many tumors applies additional pressure on tumors and contributes to
the selection of cell clones adapted to survive under the new conditions [45]. Since drug resistances
are a problem of major concern in Oncology and this issue is directly related to regional ITH, a more
efficient sampling method to clarify this problem seems mandatory.
4. The Need for an Updated Tumor Sampling Adapted to Tumor Type
The only way to discover the complex spectrum of ecological relationships and the spatial and
temporal evolution of tumors that have been revisited in previous paragraphs of this narrative is to
improve significantly the tumor representativeness with an affordable sampling. In this sense, total
tumor sampling would be the ideal solution, but it is not sustainable because many tumors are too
large to be analyzed in their entirety. For these cases international accepted protocols were designed.
At least theoretically, an effective sampling strategy must assure getting enough tissue so as to provide
reliable information in a probable subsequent molecular analysis. The benefit of such strategy should
necessarily be balanced with cost in a difficult sustainable equilibrium. At this point the key question
is: How extensive must this sampling be to assure tumor representativeness while keeping the costs
affordable? or, in other words, when to stop sampling? The answer is complex.
The strategy of getting one tissue fragment (roughly a piece of 1 cm2 in dimension) per centimeter
of tumor diameter is a rule applied to all tumors, comes from the early days of Pathology and is still
followed by pathologists worldwide. When, how and why this strategy was chosen is difficult to know.
Although our knowledge about neoplasms has dramatically improved since those days, astonishingly,
nothing has changed in tumor sampling. Instead, pathologists focus their interest on the advances
provided by -omics and other molecular advances brought by sophisticated devices and forget that
the most expensive and advanced technique may miss the target if applied in an inappropriate or
insufficient tissue sample. Once more, the simplest matters.
Internationally accepted protocols of tumor sampling state that one tumor tissue fragment per
centimeter of tumor diameter must be got for histological analysis, plus a fragment of any suspicious
area [46]. As many tumors appear homogeneous to the naked eye when sliced, tumor selection is
usually performed by the pathologist in a blind way and hidden areas of heterogeneity that may be
crucial for the patient are usually overlooked.
MSTS has been recently proposed for CCRCC (Figure 1) [13]. This approach follows the rationale
the more you sample the more you find and applies the divide and conquer algorithm [47]. This algorithm
has been already applied to resolve complex problems in physics [48], biology [49] and medicine [50],
and is based on recursively breaking down a problem in smaller parts (divide) until these are simple
enough to be solved directly (conquer). Then, partial solutions are combined to solve the original
problem. MSTS has proved to outperform routine protocols in a in silico modeling [14] and in a clinical
validation using classic histological parameters [51]. By using MSTS, it is possible to increase the
number of samples while keeping the number of cassettes fixed. For such a purpose, the size of the
samples must be trimmed from 1 cm2 to 3 mm2. This way each cassette can contain 8 small samples
per cassette (80 in total in a tumor of 10 cm in diameter) obtained from very different, distant and
representative regions of the tumor (Figure 2). A straightforward reasoning says that 80 small tissue
fragments have a higher chance for detection of ITH as compared to 10 large samples.
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Figure 1. Schematic representation of routine and multisite tumor sampling (MSTS) concepts in renal
tumors. The scheme shows the routine sampling (left) and the MSTS (right). Red cubes represent
samples at the edges of the tumor (renal sinus, extrarenal extension and interface between non-tumor
and tumor kidney) to detect tumor invasion at these levels. The green cube represents the preceptive
sample of normal kidney. Black cubes represent the tumor sampling in both strategies making use
of the same number of blocks (up to 8 small fragments can be introduced in one cassette in MSTS).
Cassettes containing tumor tissue fragments from MSTS are shown at the bottom of the picture.
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Figure 2. Multisite tumor sampling example in a clear cell renal cell carcinoma (CCRCC) showing the 
varied spectrum of histologies detected across the eight selected fragments in a single paraffin block, 
with clear cell high grade phenotype in sample 1, papillary eosinophilic in samples 2, 3, 4 and 6, solid 
eosinophilic in sample 5, and clear cell low grade in samples 7 and 8. (Hematoxylin & Eosin, original 
magnification, × 1.5 (large figure) and × 400 (figures 1 to 8)). 
If it is accepted that the paraffin block can be the unit of cost in pathology laboratories, it can be 
assumed that MSTS is better than routine sampling protocol at the same cost [14]. Finally, this method 
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Figure 2. Multisite tumor sampling example in a clear cell renal cell carcinoma (CCRCC) showing the
varied spectrum of histologies detected across the eight selected fragments in a single paraffin block,
with clear cell high grade ph notype in sample 1, papillary eosinophilic in samples 2, 3, 4 and 6, solid
eosinophilic in sample 5, and clear cell low grade in samples 7 and 8. (Hematoxylin & Eosin, original
magnification, × 1.5 (large figure) and × 400 (figures 1 to 8)).
If it is accepted that the par ffin block can be the unit of cost in pathology laboratories, it can be
assumed that MSTS is better than routine sampling protocol at the same cost [14]. Finally, this method
allows the inclusion a small fragment of normal renal tissue in each cassette that can be useful as
internal control for immunohistochemistry and/or molecular analyses. The storage of such amount
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of formalin-fixed and paraffin-embedded tumor tissue fragments in pathology laboratories may be
very useful in the future when new technologies allow better analyses. However, pathologists may be
reluctant to use MSTS because it takes a long time to collect 80 small samples in a tumor. The application
of a cutting grid to the tumor slices in the grossing room will shorten significantly the process [52].
Also, an adaptation of MSTS to large tumors arising in hollow viscera has also been proposed,
for example, for cancers arising along the digestive tract. In this particular setting, the anatomical
barrier represented by the muscularis propria leads the tumors to grow with their long axes parallel
to the wall of the viscera forming tumors with plate-like shapes, and not like spheroids as happens
in the kidney, liver or other solid organs. Instead of tissue cubes, the sampling model here gets
tissue bars including the whole thickness (from the lumen to the perivisceral adipose tissue) of the
viscera [53]. MSTS has obtained here also better performances in detecting ITH compared with routine
sampling [53].
As commented in previous paragraphs, temporal evolution in CCRCC follows several
deterministic pathways that have been defined either as branched or punctuated models [37].
The discovering of branched CCRCC would benefit specially from MSTS. This possibility makes
this strategy even more advantageous in these particular cases. Finally, the performance of MSTS to
discover ITH has also proved to be superior at any time of tumor evolution and in all models compared
with routine protocols [54].
Recent evidences, however, have demonstrated that tumor sampling must be adapted to the
tumor type to be efficient because tumor evolution and the spectrum of ITH are in fact very different,
as reflected by the range of evolutionary trees detected across different cancer types [55]. MSTS seems
to be an advantageous approach in large tumors with high ITH because in these cases getting samples
from many tumor regions will give more complete information of the whole mutational landscape.
This happens specially in tumors following branched and neutral models. By contrast, tumors with
low ITH levels, although sometimes more aggressive, apparently will not directly benefit from an
exhaustive sampling across the tumor. This may happen in neoplasms following the linear and
punctuated models.
5. Conclusions
This review is addressed to clinicians and pathologists that are involved in Oncology, and revisits
the complexity of tumor evolution with a special mention to the reasons for which each tumor is
truly unique. The definition of a more efficient method to discover this complexity is an urgent task.
Pathologists, the medical specialists who handle surgical specimens, must reconsider if the currently
accepted protocols for tumor sampling are appropriate enough to offer with reliability the expected
answers that precision medicine needs today. In this regard, new sampling methods could provide
substantial advantages for a more precise diagnosis in a subset of cases. MSTS could be a good option
since it keeps the balance cost/benefit sustainable.
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